文献速递妇科

晚期子宫内膜癌通用与选择性二代测序的成本与效率

Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2026-01-01

本研究构建决策树模型,比较新诊断III-IVA期子宫内膜癌的三种分子分型策略:MMR/p53、选择性NGS和通用NGS,分子亚型患病率和6年无复发生存率源自GOG-0258随机试验。结果显示通用NGS在未复发患者中造成57%的不必要检测,而选择性NGS仅7%,MMR/p53为0%;MMR/p53成本最低(平均3772美元),其次为选择性NGS(4186美元)和通用NGS(6250美元)。结论认为对p53异常肿瘤反射性NGS的选择性策略可提高检测效率并减少不必要NGS。

要点

  • 通用NGS在未复发患者中不必要检测率达57%,选择性NGS仅7%。
  • MMR/p53策略成本最低(平均3772美元),通用NGS最高(6250美元)。
  • 选择性NGS较MMR/p53每增加一个及时NGS结果多花费2571美元。

核心结论

  • 对新诊断III-IVA期子宫内膜癌采用MMR/p53免疫组化并对p53异常者反射性NGS的选择性策略,较通用 upfront NGS提高检测效率并减少不必要NGS。

研究设计与样本

  • 构建决策树模型比较三种分子分型策略,分子亚型患病率和6年无复发生存率源自GOG-0258随机试验。

主要发现

  • 通用NGS在未复发患者中不必要NGS比例为57%,选择性NGS为7%,MMR/p53为0%。
  • MMR/p53平均成本3772美元,选择性NGS为4186美元,通用NGS为6250美元。
  • 选择性NGS较MMR/p53每增加一个及时NGS结果成本为2571美元。
  • 通用NGS较选择性NGS每增加一个及时NGS结果成本为7600美元。

临床怎么用

  • 对新诊断III-IVA期子宫内膜癌可优先采用MMR/p53免疫组化,仅对p53异常者即时行NGS,以减少不必要检测并降低成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to identify efficient tumor molecular profiling strategies for patients with newly diagnosed stage III-IVA endometrial cancer. METHODS: We constructed a decision tree model to compare molecular profiling strategies. We considered testing options of mismatch repair (MMR), p53, and HER2 immunohistochemistry (IHC), and next generation sequencing (NGS, assessing for MMR protein, TP53 and POLE mutations). Strategies included (1) MMR/p53: MMR/p53 IHC at diagnosis, with HER2 IHC if p53 abnormal and NGS reserved for first progression/recurrence; (2) Selective NGS: MMR/p53 IHC at diagnosis, with immediate NGS and HER2 IHC if p53 abnormal, otherwise NGS at recurrence; (3) Universal NGS: NGS and HER2 IHC at diagnosis for all. Molecular subtype prevalence and six-year recurrence-free survival by subtype were derived from the GOG-0258 randomized trial. Outcomes included costs (2024 US$), timely NGS results (results available at recurrence/progression), and unnecessary NGS (NGS performed in patients who remained recurrence-free). RESULTS: Universal NGS resulted in unnecessary NGS in 57% of patients who remained recurrence-free, compared with 7% under the Selective NGS strategy and 0% with MMR/p53. MMR/p53 was the least costly strategy (mean cost $3772), followed by Selective NGS ($4186) and Universal NGS ($6250). Compared with MMR/p53, Selective NGS cost $2571 per additional timely NGS result, while Universal NGS cost $7600 per additional timely NGS result compared with Selective NGS. CONCLUSIONS: Selective molecular profiling of newly diagnosed stage III-IVA endometrial cancers using MMR and p53 IHC with reflex to NGS for p53-abnormal tumors improves testing efficiency and reduces unnecessary NGS compared with universal upfront NGS testing.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bashi A, Penvose KN, Wright JD, et al. Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer. Gynecol Oncol. 2026. PMID: 42000378. doi:10.1016/j.ygyno.2026.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。